Miami, FL – May 4, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, Mateon Therapeutics, Inc. (OTCQB: MATN).
In conversation with Saran Saund — A Silicon Valley serial entrepreneur rising to the current challenges with the pandemic by bridging the Ancient wisdom sciences (Ayurveda/TC) with cutting edge science, technology – AI/Machine Learning, NLP! We also discuss Digital Therapeutics, Transformative technology and how we can emerge as a more compassionate collective through this adversity.
We discuss how ‘Artemisinin’ is a drug derived from the Asian plant Artemisia annua, can potentially help with COVID19. This aromatic plant has fern-like leaves and yellow flowers. For more than 2,000 years, it has been used to treat fevers.
Saran Saud was the former CEO of PointR Data Inc., which was acquired by Mateon. He is currently the Chief Business Officer (CBO)/ General Manager of AI Division at Mateon.
Our research led us to believe that COVID-19 is a TGF-β driven disease. COVID-19 virus induction of TGF-β resulting in cell cycle arrest and hikacking the cellular machinery to make more COVID-19 virus. As more and more cells are infected the level of TGF-β goes up and once it crosses the normal physiological threshold, the body responds as though it was under attack. Fluid starts moving in the lung, neutrophils start coming in and laying fibrin network with resulting clots, and we go from acute lung injury to full blown acute respiratory distress syndrome. All driven by TGF-β.
As part of our drug discovery program, we have examined other TGF-β inhibitors and found artemisinin with potent anti-COVID 19 activity against cell base replication assay. The mechanism is through artemisinin suppression of TGF-β. The free radical mechanism is only activated in presence of free ferritin occurring only during active malaria infection and is not involved as mechanism of action against COVID-19.
Our goal is to continue development of OT-101 against COVID-19 and we are starting clinical development soon with IND submission to FDA completed and in final phase of clinical protocol discussion. While we lead the OT-101 development against COVID-19, we want to world to know that artemisinin will also work. Here our focus is to get the word out and for countries that do not have access to expensive drug, to use artemisinin as a poor man replacement for COVID-19 drugs (ours – OT-101/ or Gilead Remdesivir). This is being undertaken as a humanitarian effort to save lives. We are not interested in developing artemisinin as a herbal supplement against COVID-19. As it is right now- anyone can take artemisinin off the shelf as herbal supplement. We would caution that herbal supplements are not all equal in quality and this antiviral activity is new and never been described for artemisinin.
“Our focus is to save lives now versus waiting until a drug or a vaccine can be developed- by that time many lives would have been lost and the pandemic would have left survivors in financial ruin. It took a long time for the millions to pull themselves out of poverty and this is pushing them back in an eyeblink. It is not something that we can stand idly by” said Saran Saund, CBO of Mateon Therapeutics.
Mateon’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “innovative”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.
For Mateon Therapeutics, Inc.:
Source: Mateon Therapeutics
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.